본문 바로가기
KERD
논문KCI 등재

Summary of the 2023 Thai Menopause Society Clinical Practice Guideline on Menopausal Hormone Therapy

Unnop Jaisamrarn|Sukanya Chaikittisilpa|Nalina Orprayoon|Orawin Vallibhakara|Sakda Arj-Ong Vallibhakara|Prasong Tanmahasamut|Woraluk Somboonporn|Manee Rattanachaiyanont|Kitirat Techatraisak
대한폐경학회 (Korean Society Of Menopause)|2024.04|대한폐경학회지 (Journal of Menopausal Medicine)|제30권 제1호|pp. 24-36|DOI 10.6118/jmm.24006

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

Cardiovascular diseasesMenopauseHormone therapyGenitourinary syndrome of menopauseVasomotor symptoms

초록

The Thai Menopause Society is an academic organization consisting of healthcare professionals engaged in menopause medicine. The position statement was first issued in 1994 and updated in 2003 and 2023. Herein, we reviewed the important updates of the 2023 position statement on menopausal hormone therapy (MHT) as an international reference for healthcare professionals in Thailand. An advisory panel of clinicians and research experts in the field of menopause reviewed the recommendation of published International Consensus Statements and updated the evidence using the MEDLINE database through PubMed. The evidence-based information and relevant publications were assessed, and a consensus on recommendations was subsequently achieved using the level of evidence to determine the recommendation strength and evidence quality. MHT remains the most effective treatment for vasomotor symptoms and genitourinary syndromes of menopause even after 20 years. Additionally, it is effective in preventing bone loss and fractures in postmenopausal women. The cardiovascular risk of MHT increased in women who initiated MHT after 60 years of age. Hormone therapy should be individualized following the hormone type, dose, administration route, use duration, and progestogen inclusion. The necessary pretreatment evaluation and appropriate follow-up recommendations were added for improved MHT standard care. The updated 2023 Clinical Practice Guideline on MHT is useful for gynecologists, general physicians, endocrinologists, and other healthcare professionals in treating menopausal women receiving hormone therapy in Thailand.

Abstract

The Thai Menopause Society is an academic organization consisting of healthcare professionals engaged in menopause medicine. The position statement was first issued in 1994 and updated in 2003 and 2023. Herein, we reviewed the important updates of the 2023 position statement on menopausal hormone therapy (MHT) as an international reference for healthcare professionals in Thailand. An advisory panel of clinicians and research experts in the field of menopause reviewed the recommendation of published International Consensus Statements and updated the evidence using the MEDLINE database through PubMed. The evidence-based information and relevant publications were assessed, and a consensus on recommendations was subsequently achieved using the level of evidence to determine the recommendation strength and evidence quality. MHT remains the most effective treatment for vasomotor symptoms and genitourinary syndromes of menopause even after 20 years. Additionally, it is effective in preventing bone loss and fractures in postmenopausal women. The cardiovascular risk of MHT increased in women who initiated MHT after 60 years of age. Hormone therapy should be individualized following the hormone type, dose, administration route, use duration, and progestogen inclusion. The necessary pretreatment evaluation and appropriate follow-up recommendations were added for improved MHT standard care. The updated 2023 Clinical Practice Guideline on MHT is useful for gynecologists, general physicians, endocrinologists, and other healthcare professionals in treating menopausal women receiving hormone therapy in Thailand.

참고문헌 (100)

  1. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Womenʼs Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
  2. Prentice RL, "Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50-59 years of age", Am J Epidemiol, 190, pp.365~375 (2021)
  3. Baber RJ, "2016 IMS recommendations on womenʼs midlife health and menopause hormone therapy", Climacteric, 19, pp.109~150 (2016)
  4. Faubion SS, "The 2022 hormone therapy position statement of the North American Menopause Society", Menopause, 29, pp.767~794 (2022)
  5. Okano H, "Japan Society of Obstetrics and Gynecology and Japan Society for Menopause and Womenʼs Health 2017guidelines for hormone replacement therapy", J Obstet Gynaecol Res, 44, pp.1355~1368 (2018)
  6. Shekelle PG, "Developing clinical guidelines", West J Med, 170, pp.348~351 (1999)
  7. Atkins D, "Systems for grading the quality of evidence and the strength of recommendations I : critical appraisal of existing approaches The GRADE Working Group", BMC Health Serv Res, 4, pp.38~ (2004)
  8. Shiffman RN, "Standardized reporting of clinical practice guidelines : a proposal from the conference on guideline standardization", Ann Intern Med, 139, pp.493~498 (2003)
  9. Maclennan AH, "Oral oestrogen and combined oestrogen", progestogen therapy versus placebo for hot flushes, 2004, pp.2004, CD002978~
  10. Santoro N, "Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo : the Kronos early estrogen prevention study", Menopause, 24, pp.238~246 (2017)
  11. Bachmann GA, "Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women : a randomized controlled trial", Obstet Gynecol, 110, pp.771~779 (2007)
  12. Brunner RL, "Menopausal symptom experience before and after stopping estrogen therapy in the Womenʼs Health Initiative randomized, placebo-controlled trial", Menopause, 17, pp.946~954 (2010)
  13. Ockene JK, "Symptom experience after discontinuing use of estrogen plus progestin", JAMA, 294, pp.183~193 (2005)
  14. Hitchcock CL, "Oral micronized progesterone for vasomotor symptoms-a placebo-controlled randomized trial in healthy postmenopausal women", Menopause, 19, pp.886~893 (2012)
  15. Prior JC, "Progesterone for treatment of symptomatic menopausal women", Climacteric, 21, pp.358~365 (2018)
  16. Formoso G, "Short-term and long-term effects of tibolone in postmenopausal women", Cochrane Database Syst Rev, 10, pp.CD008536~ (2016)
  17. Biehl C, "A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause", Menopause, 26, pp.431~453 (2019)
  18. Cody JD, "Oestrogen therapy for urinary incontinence in post-menopausal women", Cochrane Database Syst Rev, 10, pp.CD001405~ (2012)
  19. Brown JS, "Urinary tract infections in postmenopausal women : effect of hormone therapy and risk factors", Obstet Gynecol, 98, pp.1045~1052 (2001)
  20. Raz R, "A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections", N Engl J Med, 329, pp.753~756 (1993)
  21. Cauley JA, "Effects of estrogen plus progestin on risk of fracture and bone mineral density : the Womenʼs Health Initiative randomized trial", JAMA, 290, pp.1729~1738 (2003)
  22. Manson JE, "Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Womenʼs Health Initiative randomized trials", JAMA, 310, pp.1353~1368 (2013)
  23. Cummings SR, "The effects of tibolone in older postmenopausal women", N Engl J Med, 359, pp.697~708 (2008)
  24. Soares CN, "Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women : a double-blind, randomized, placebo-controlled trial", Arch Gen Psychiatry, 58, pp.529~534 (2001)
  25. Schmidt PJ, "Effects of estradiol withdrawal on mood in women with past perimenopausal depression : a randomized clinical trial", JAMA Psychiatry, 72, pp.714~726 (2015)
  26. Cintron D, "Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study(KEEPS)", Menopause, 25, pp.145~153 (2018)
  27. Proserpio P, "Insomnia and menopause : a narrative review on mechanisms and treatments", Climacteric, 23, pp.539~549 (2020)
  28. Cintron D, "Efficacy of menopausal hormone therapy on sleep quality : systematic review and meta-analysis", Endocrine, 55, pp.702~711 (2017)
  29. Espeland MA, "Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50to 55 years", JAMA Intern Med, 173, pp.1429~1436 (2013)
  30. Gleason CE, "Effects of hormone therapy on cognition and mood in recently postmenopausal women : findings from the randomized, controlled KEEPS-cognitive and affective study", PLoS Med, 12, pp.e1001833~ (2015)
  31. Lethaby A, "Hormone replacement therapy for cognitive function in postmenopausal women", Cochrane Database Syst Rev, pp.CD003122~ (2008)
  32. Miller VT, "Effects of estrogen or estrogen", progestin regimens on heart disease risk factors in postmenopausal women : the postmenopausal estrogen, JAMA, pp.1995, 273[DOI]
  33. Anagnostis P, "The effect of hormone replacement therapy and tibolone on lipoprotein(a)concentrations in postmenopausal women : a systematic review and meta-analysis", Maturitas, 99, pp.27~36 (2017)
  34. Chu MC, "A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome", Fertil Steril, 86, pp.1669~1675 (2006)
  35. Boardman HM, "Hormone therapy for preventing cardiovascular disease in post-menopausal women", Cochrane Database Syst Rev, 2015, pp.CD002229~ (2015)
  36. Rovinski D, "Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy : a systematic review and meta-analysis", Thromb Res, 168, pp.83~95 (2018)
  37. Bergendal A, "Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri-and postmenopausal women and in relation to type and route of administration", Menopause, 23, pp.593~599 (2016)
  38. Manson JE, "Menopausal hormone therapy and long-term all-cause and cause-specific mortality : the womenʼs health initiative randomized trials", JAMA, 318, pp.927~938 (2017)
  39. Yang Z, "Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women : a systematic review and meta-analysis", Gynecol Endocrinol, 33, pp.87~92 (2017)
  40. Fournier A, "Unequal risks for breast cancer associated with different hormone replacement therapies : results from the E3N cohort study", Breast Cancer Res Treat, 107, pp.103~111 (2008)
  41. Collaborative Group on Hormonal Factors in Breast Cancer, "Type and timing of menopausal hormone therapy and breast cancer risk : individual participant meta-analysis of the worldwide epidemiological evidence", Lancet, 394, pp.1159~1168 (2019)
  42. Furness S, "Hormone therapy in postmenopausal women and risk of endometrial hyperplasia", Cochrane Database Syst Rev 2012;, 2012, pp.CD000402~ (2012)
  43. Sjögren LL, "Hormone replacement therapy and the risk of endometrial cancer : a systematic review", Maturitas, 91, pp.25~35 (2016)
  44. Weiderpass E, "Risk of endometrial cancer following estrogen replacement with and without progestins", J Natl Cancer Inst, 91, pp.1131~1137 (1999)
  45. Somboonporn W, "Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women : systematic review and meta-analysis", Menopause, 18, pp.1060~1066 (2011)
  46. Liu Y, "Menopausal hormone replacement therapy and the risk of ovarian cancer : a metaanalysis", Front Endocrinol (Lausanne), 10, pp.801~ (2019)
  47. Simin J, "Menopausal hormone therapy and cancer risk : an overestimated risk?", Eur J Cancer, 84, pp.60~68 (2017)
  48. Shi LF, "Hormone therapy and risk of ovarian cancer in postmenopausal women : a systematic review and metaanalysis", Menopause, 23, pp.417~424 (2016)
  49. Schwartz AG, "Hormone use, reproductive history, and risk of lung cancer : the womenʼs health initiative studies", J Thorac Oncol, 10, pp.1004~1013 (2015)
  50. Grodstein F, "Postmenopausal hormone therapy and the risk of colorectal cancer : a review and meta-analysis", Am J Med, 106, pp.574~582 (1999)
  51. LaCroix AZ, "Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy : a randomized controlled trial", JAMA, 305, pp.1305~1314 (2011)
  52. Brusselaers N, "Menopausal hormone therapy and the risk of esophageal and gastric cancer", Int J Cancer, 140, pp.1693~1699 (2017)
  53. Camargo MC, "Sex hormones, hormonal interventions, and gastric cancer risk : a meta-analysis", Cancer Epidemiol Biomarkers Prev, 21, pp.20~38 (2012)
  54. McGlynn KA, "Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink", Int J Cancer, 138, pp.2146~2153 (2016)
  55. Zhong GC, "Reproductive factors, menopausal hormone therapies and primary liver cancer risk : a systematic review and dose-response metaanalysis of observational studies", Hum Reprod Update, 23, pp.126~138 (2016)
  56. Taaffe DR, "The effect of hormone replacement therapy and", or exercise on skeletal muscle attenuation in postmenopausal women : a yearlong intervention, 2005, pp.25, 297~304
  57. Ronkainen PH, "Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function : a study with monozygotic twin pairs", J Appl Physiol(1985), 107, pp.25~33 (2009)
  58. Surazynski A, "Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts", Int J Mol Med, 12, pp.803~809 (2003)
  59. Jung JH, "Knee osteoarthritis and menopausal hormone therapy in postmenopausal women : a nationwide cross-sectional study", Menopause, 26, pp.598~602 (2018)
  60. Cirillo DJ, "Effect of hormone therapy on risk of hip and knee joint replacement in the Womenʼs Health Initiative", Arthritis Rheum, 54, pp.3194~3204 (2006)
  61. Sator PG, "A prospective, randomized, double-blind, placebocontrolled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women", Climacteric, 10, pp.320~334 (2007)
  62. Wilkinson HN, "The role of estrogen in cutaneous ageing and repair", Maturitas, 103, pp.60~64 (2017)
  63. Cervenka I, "Postmenopausal hormone use and cutaneous melanoma risk : a French prospective cohort study", Int J Cancer, 145, pp.1754~1767 (2019)
  64. Botteri E, "Menopausal hormone therapy and risk of melanoma : do estrogens and progestins have a different role?", Int J Cancer, 141, pp.1763~1770 (2017)
  65. Cirillo DJ, "Effect of estrogen therapy on gallbladder disease", JAMA, 293, pp.330~339 (2005)
  66. Marjoribanks J, "Longterm hormone therapy for perimenopausal and postmenopausal women", Cochrane Database Syst Rev, 1, pp.CD004143~ (2017)
  67. Gandhi J, "Genitourinary syndrome of menopause : an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management", Am J Obstet Gynecol, 215, pp.704~711 (2016)
  68. Rahn DD, "Vaginal estrogen for genitourinary syndrome of menopause : a systematic review", Obstet Gynecol, 124, pp.1147~1156 (2014)
  69. Lethaby A, "Local oestrogen for vaginal atrophy in postmenopausal women", Cochrane Database Syst Rev, 2016, pp.CD001500~ (2016)
  70. Rudolph I, "Influence of a continuous combined HRT(2 mg estradiol valerate and 2 mg dienogest)on postmenopausal depression", Climacteric, 7, pp.301~311 (2004)
  71. Watt FE, "Hand osteoarthritis, menopause and menopausal hormone therapy", Maturitas, 83, pp.13~18 (2016)
  72. Faubion SS, "Long-term health consequences of premature or early menopause and considerations for management", Climacteric, 18, pp.483~491 (2015)
  73. Atsma F, "Postmenopausal status and early menopause as independent risk factors for cardiovascular disease : a meta-analysis", Menopause, 13, pp.265~279 (2006)
  74. Muka T, "Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality : a systematic review and meta-analysis", JAMA Cardiol, 1, pp.767~776 (2016)
  75. Torgerson DJ, "Hormone replacement therapy and prevention of vertebral fractures : a meta-analysis of randomised trials", BMC Musculoskelet Disord, 2, pp.7~ (2001)
  76. Torgerson DJ, "Hormone replacement therapy and prevention of nonvertebral fractures : a meta-analysis of randomized trials", JAMA, 285, pp.2891~2897 (2001)
  77. Holmberg L, "HABITS(hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison : trial stopped", Lancet, 363, pp.453~455 (2004)
  78. Anderson GL, "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Womenʼs Health Initiative randomized controlled trial", JAMA, 291, pp.1701~1712 (2004)
  79. Shim SH, "Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors : a meta-analysis", Eur J Cancer, 50, pp.1628~1637 (2014)
  80. Li D, "Postoperative hormone replacement therapy for epithelial ovarian cancer patients : a systematic review and meta-analysis", Gynecol Oncol, 139, pp.355~362 (2015)
  81. Pinkerton JV, "The 2017 hormone therapy position statement of the North American Menopause Society", Menopause, 24, pp.728~753 (2017)
  82. Goldenberg NM, "An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia", Clin Chim Acta, 332, pp.11~19 (2003)
  83. Salpeter SR, "Meta-analysis : effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women", Diabetes Obes Metab, 8, pp.538~554 (2006)
  84. Hodis HN, "Vascular effects of early versus late postmenopausal treatment with estradiol", N Engl J Med, 374, pp.1221~1231 (2016)
  85. Slopien R, "Menopause and diabetes : EMAS clinical guide", Maturitas, 117, pp.6~10 (2018)
  86. Shimizu I, "Impact of oestrogens on the progression of liver disease", Liver Int, 23, pp.63~69 (2003)
  87. Rinaldi M, "Neutral effect of prolonged transdermal hormone therapy on liver function of postmenopausal women with chronic active hepatitis", Menopause, 12, pp.619~622 (2005)
  88. Mohammed K, "Oral vs transdermal estrogen therapy and vascular events : a systematic review and meta-analysis", J Clin Endocrinol Metab, 100, pp.4012~4020 (2015)
  89. Botto N, "Prothrombotic mutations, family history and the risk of thrombosis in postmenopausal women : implications for hormone replacement therapy", Climacteric, 14, pp.25~30 (2011)
  90. Angchaisuksiri P, "Prevalence of the G1691A mutation in the factor V gene(factor V Leiden)and the G20210A prothrombin gene mutation in the Thai population", Am J Hematol, 65, pp.119~122 (2000)
  91. Lethaby A, "Hormone replacement therapy in postmenopausal women : endometrial hyperplasia and irregular bleeding", Cochrane Database Syst Rev, (3), pp.CD000402~ (2004)
  92. Pike MC, "Estrogen-progestin replacement therapy and endometrial cancer", J Natl Cancer Inst, 89, pp.1110~1116 (1997)
  93. Roberts H, "Hormone therapy in postmenopausal women and risk of endometrial hyperplasia : a Cochrane review summary", Maturitas, 77, pp.4~6 (2014)
  94. Judd HL, "Effects of hormone replacement therapy on endometrial histology in postmenopausal women : the postmenopausal estrogen", progestin interventions(PEPI)trial, 1996, pp.275, 370~375
  95. Anderson GL, "Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures : the Womenʼs Health Initiative randomized trial", JAMA, 290, pp.1739~1748 (2003)
  96. Scarabin PY, "Progestogens and venous thromboembolism in menopausal women : an updated oral versus transdermal estrogen meta-analysis", Climacteric, 21, pp.341~345 (2018)
  97. Becker CM, "ESHRE guideline : endometriosis", Hum Reprod Open, 2022, pp.hoac009~ (2022)
  98. Islam RM, "Safety and efficacy of testosterone for women : a systematic review and meta-analysis of randomised controlled trial data", Lancet Diabetes Endocrinol, 7, pp.754~766 (2019)
  99. The position Statement on Breast Cancer Screening, "National Cancer Institute", National Cancer Institute, ~ (2018)
  100. Charatcharoenwitthaya N, "Summary of the Thai Osteoporosis Foundation(TOPF)clinical practice guideline on the diagnosis and management of osteoporosis 2021", Osteoporos Sarcopenia, 9, pp.45~52 (2023)

관련 논문AI추천

Asia-Pacific Menopause Federation Consensus Statement on the Management of Menopause 2024Choon Moy Ho, Enkhee Sodnomdorj, Felicia Clara Jun Hui Tan, Jignesh Shah, Ma Corazon Zaida Noblejas-Gamilla, Masakazu Terauchi, Mee-Ran Kim, Muhammad Fidel Ganis Siregar, Qi Yu, Rubina Hussain, Seng Bin Ang, Shaikh Zinnat Ara Nasreen, Sonia Davison, Stella Rizalina Sasha Sugianto, Unnop Jaisamrarn, Yang Chua, Yung-Chieh Tsai대한폐경학회 · 대한폐경학회지2025 · 제31권 제1호폐경기 증상을 완화시키기 위한 개별화 호르몬 요법에 대한 고찰: 다른 위험요소가 없는 폐경기 여성을 중심으로윤휘열, 이영미한국임상약학회 · 한국임상약학회지2017 · 제27권 제4호Insights into Singaporean Physicians’ Knowledge and Attitudes on Menopause Hormone TherapyAng Seng Bin, Dypti Lulla, Farah Safdar Husain, Ieera Aggarwal, Jean-Jasmin ML Lee, Rukshini Puvanendran, Satvinder Singh Dhaliwal, Stella Rizalina Sasha Sugianto대한폐경학회 · 대한폐경학회지2025 · 제31권 제3호Review of hormonal replacement therapy options for the treatments of menopausal symptomsAngelia Veronica, Christoper Andreas, Edelweishia Melissa, Theresia Evelyne대한가정의학회 · Korean Journal of Family Medicine2025 · 제46권 제5호The 2020 Menopausal Hormone Therapy Guidelines윤보현, Academic Committee of the Korean Society of Menopause, Dong Ock Lee, Dong-Yun Lee, Eun Sil Lee, Gyun-Ho Jeon, Hee Dong Chae, Jae Yen Song, Jong Kil Joo, Jung-Ho Shin, Kyong Wook Yi, Kyu Ri Hwang, Moon Kyoung Cho, Sa Ra Lee, Seul Ki Kim, Seung-Hwa Hong, Sungwook Chun, Tak Kim, Yeon Jean Cho대한폐경학회 · 대한폐경학회지2020 · 제26권 제2호Hormone Therapy in the Era of the COVID-19 Pandemic: A Review이재훈, Hee Dong Chae, Juhee Kim, Sa Ra Lee, Seul Ki Kim, Sung Hoon Kim, Sung Wook Choi대한폐경학회 · 대한폐경학회지2022 · 제28권 제1호

이 간행물의 다른 논문 (3건)

The 2024 Guidelines for Osteoporosis - Korean Society of Menopause이지영, Paik Haerin, Yi Kyong Wook, Shin Jung-Ho, Park Hyun-Tae, Lee Sa Ra, Kim Jinju, Hwang Kyu Ri, Hong Seung Hwa, Chung Youn-Jee, Chun Sungwook, Cho Moon Kyoung, Hong Yeon Hee, Lee Dong Ock, 송재연, 서석교, 최영식, 김훈, 이동윤pp. 1-23Modulation of Bone Mineral Density and Its Response to Menopausal Hormone Therapy according to the Apolipoprotein E Genotype in Postmenopausal Korean WomenMin Yong-Ki, Lim Hyun Hye, Yoon Sun-Kee, Kim Woosun, Yoon Byung-Koo, Seo Jong-Wook, Shin Whanpp. 37-43Determinants of Sexual Health Status of Menopausal Women in Osun State, NigeriaOlowokere Adekemi Eunice, Adedeji Ademidun Oluwatoyin, Olajubu Aanuoluwapo Omobolanle, Aladegboye Mercy Kikelomopp. 44-53
원문 보기